Itraconazol 1 A Pharma

Itraconazole, the active ingredient in Itraconazol 1 A Pharma, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections, including dermatophyte skin infections, candidiasis, and invasive mycoses in adult patients.

GNH USA supplies Itraconazol 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Itraconazole is used to treat fungal infections across several disease categories.

- Dermatophyte infections: effective for treating skin, nail and hair infections caused by dermatophyte fungi. - Candidiasis: clears yeast infections of the mouth, throat, esophagus and genital areas. - Aspergillosis: used for invasive disease caused by Aspergillus species. - Histoplasmosis: treats systemic infection from Histoplasma capsulatum. - Blastomycosis: manages disseminated infection caused by Blastomyces dermatitidis.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often reported during early therapy. - Headache: transient headache occurring in some patients. - Diarrhea: loose stools that usually resolve without intervention. - Elevated liver enzymes: mild, reversible increase in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring discontinuation. - Congestive heart failure exacerbation: fluid retention leading to worsening cardiac function. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Itraconazole, clinicians should consider several precautionary measures to ensure safe use.

- Liver function monitoring: assess baseline hepatic enzymes and repeat during therapy. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. - Concomitant medications: review for potential interactions that may increase itraconazole levels. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Patient counseling: advise to take the medication with food to enhance absorption. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Itraconazole interacts with several medicines through metabolic pathways and transport proteins.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce itraconazole exposure. - Certain statins (e.g., simvastatin, lovastatin): increased risk of myopathy and rhabdomyolysis. - P-glycoprotein substrates (e.g., digoxin): elevated plasma concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Benzodiazepines (midazolam, triazolam): increased sedation, dose adjustment may be needed. - HIV protease inhibitors (ritonavir): can raise itraconazole levels, monitor for toxicity.